Overview

Spironolactone Against Anthracycline-induced Cardiomyopathy

Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
This study sought to investigate the whether spironolactone protects the heart against anthracycline-induced cardiotoxicity.
Phase:
Phase 4
Details
Lead Sponsor:
TC Erciyes University
Treatments:
Spironolactone